Potential conflict of interest: All authors have indicated that they have nothing to disclose regarding Wellness Health and Pharmaceuticals or glutathione. Dr. Robert Hauser has received honoraria or consulting fees from Bayer Schering Pharma AG, Bertek, Boehringer Ingelheim, Centopharm, Eisai, Genzyme, GlaxoSmithKline, Impax, Kyowa Pharmaceutical, Merck KgaA, Ortho McNeil, Novartis, Pfizer, Prestwick, Schwarz Pharma, Schering, Solvay, Synosia, Teva Neuroscience, Valeant, and Vernalis. Dr. Kelly Lyons has received honoraria or consulting fees from Advanced Neuromodulation Systems, GlaxoSmithKline, Novartis, Teva Neuroscience, UCB Pharma, and Valeant Pharmaceuticals. Terry McClain has received honoraria or consulting fees from Eisai, GlaxoSmithKline, Kyowa Pharmaceutical, Solvay, Teva Neuroscience, Serono, and Vernalis. Summer Carter has received honoraria or consulting fees from Solvay and Asubio Pharmaceuticals. Dr. David Perlmutter reports nothing to disclose.
Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease†
Version of Record online: 19 FEB 2009
Copyright © 2009 Movement Disorder Society
Volume 24, Issue 7, pages 979–983, 15 May 2009
How to Cite
Hauser, R. A., Lyons, K. E., McClain, T., Carter, S. and Perlmutter, D. (2009), Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov. Disord., 24: 979–983. doi: 10.1002/mds.22401
- Issue online: 28 MAY 2009
- Version of Record online: 19 FEB 2009
- Manuscript Accepted: 24 OCT 2008
- Manuscript Revised: 20 AUG 2008
- Manuscript Received: 8 JUL 2008
- Wellness Health and Pharmaceuticals (Birmingham, Alabama)
Additional Supporting Information may be found in the online version of this article.
|mds22401supptable1.doc||52K||Supporting Information Table 1. Baseline medications for each subject.|
|mds22401supptable2.doc||36K||Supporting Information Table 2. Means (SD) for UPDRS scores, walking time and tapping for placebo and glutathione groups. P-values represent changes in glutathione vs. changes in placebo from baseline to week 4 (treatment period) and from week 4 to week 12 (no treatment follow-up period).|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.